Application to market givinostat for DMD in Europe under ...
The EMA is reviewing givinostat for Duchenne muscular dystrophy (DMD) treatment, following a similar FDA priority review. Givinostat blocks HDACs to potentially improve muscle repair and strength, based on Phase 3 trial results showing slowed motor function decline and delayed muscle fat build-up in DMD patients.
Related Clinical Trials
Reference News
Application to market givinostat for DMD in Europe under ...
The EMA is reviewing givinostat for Duchenne muscular dystrophy (DMD) treatment, following a similar FDA priority review. Givinostat blocks HDACs to potentially improve muscle repair and strength, based on Phase 3 trial results showing slowed motor function decline and delayed muscle fat build-up in DMD patients.